The Claim
GLP-1 receptor agonists confer a similar relative risk reduction of major adverse cardiovascular events in patients with type 2 diabetes regardless of the presence or absence of pre-existing atherosclerotic cardiovascular disease, with hazard ratios of 0.83 and 0.89, respectively.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with type 2 diabetes, GLP-1 receptor agonists reduce the risk of major heart events by a similar proportion whether or not they already have artery disease.
See the scientific wording
The relative risk reduction of major adverse cardiovascular events (MACE) from GLP-1 receptor agonists is similar in type 2 diabetes patients with and without pre-existing atherosclerotic cardiovascular disease, with hazard ratios of 0.83 and 0.89 respectively, indicating that the proportional benefit is consistent regardless of baseline cardiovascular risk.
GLP-1 receptor agonists lower inflammation in blood vessels, reduce fat buildup in artery walls, and make existing plaques less likely to rupture, which prevents heart attacks and strokes in all patients with type 2 diabetes, whether or not they already had heart disease.
What the research says
1 studyThe study found that GLP-1 drugs lower the risk of heart problems by about the same percentage—11% to 17%—in people with and without prior heart disease, even though the actual number of prevented events is higher in those who already had heart disease.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.